Targets › SLC39A6
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2030.
Zinc-influx transporter which plays a role in zinc homeostasis and in the induction of epithelial-to-mesenchymal transition (EMT). When associated with SLC39A10, the heterodimer formed by SLC39A10 and SLC39A6 mediates cellular zinc uptake to trigger cells to undergo epithelial- to-mesenchymal transition (EMT). (UniProt, Q13433)
Open in Phaseline: the race on SLC39A6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Ladiratuzumab Vedotin Tubulin inhibitor; Zinc transporter ZIP6 binding agent | Tubulin, SLC39A6 | Phase 1 | Metastatic Breast Cancer | Sep 2030 |
Metastatic Breast Cancer (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.